Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

Constenla Figueiras, Manuel
Thumbnail
Statistics
Statistics
Identifiers
Identifiers
URI: http://hdl.handle.net/20.500.11940/2126
PMID: 23359181
ISSN: 1699-048X
Full record
Services
Services
RISMendeleyLinksolver
Date issued
2013
Journal title
Clinical & Translational Oncology
Type of content
Artigo